Amendment: SEC Form 25-NSE/A filed by Merus N.V.

12/30/25 9:04:23 AM ET

$MRUS

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $MRUS alert in real time by email

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

UNITED STATES

OMB APPROVAL

OMB Number:		3235-0080
Expires:	March 31, 2018
Estimated average burden
hours per response:		1.7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

001-37773

Issuer:	Merus N.V.
Exchange:	Nasdaq Stock Market LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address:	Padualaan 8 (postvak 133)
	Utrecht	NETHERLANDS	3584 CH
Telephone number:				+31 0 30 253 8816

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

common stock

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

2025-12-30	By	Tara Petta		AVP
Date		Name		Title

¹	Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Get the next $MRUS alert in real time by email

Recent Analyst Ratings for

$MRUS

Date	Price Target	Rating	Analyst
9/17/2025	$112.00	Overweight	Barclays
8/25/2025	$90.00	Buy	Alliance Global Partners
2/13/2025	$84.00	Overweight	Piper Sandler
2/7/2025	$91.00	Overweight	Wells Fargo
11/21/2024	$73.00	Buy	Goldman
10/24/2024	$72.00	Buy	UBS
3/28/2024	$69.00	Buy	Truist
3/4/2024	$42.00 → $65.00	Buy	Needham

More analyst ratings

Amendment: SEC Form 25-NSE/A filed by Merus N.V.

12/30/25 9:04:23 AM ET

$MRUS

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $MRUS alert in real time by email

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

UNITED STATES

OMB APPROVAL

OMB Number:		3235-0080
Expires:	March 31, 2018
Estimated average burden
hours per response:		1.7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

001-37773

Issuer:	Merus N.V.
Exchange:	Nasdaq Stock Market LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address:	Padualaan 8 (postvak 133)
	Utrecht	NETHERLANDS	3584 CH
Telephone number:				+31 0 30 253 8816

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

common stock

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

2025-12-30	By	Tara Petta		AVP
Date		Name		Title

¹	Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Get the next $MRUS alert in real time by email

Recent Analyst Ratings for

$MRUS

Date	Price Target	Rating	Analyst
9/17/2025	$112.00	Overweight	Barclays
8/25/2025	$90.00	Buy	Alliance Global Partners
2/13/2025	$84.00	Overweight	Piper Sandler
2/7/2025	$91.00	Overweight	Wells Fargo
11/21/2024	$73.00	Buy	Goldman
10/24/2024	$72.00	Buy	UBS
3/28/2024	$69.00	Buy	Truist
3/4/2024	$42.00 → $65.00	Buy	Needham

More analyst ratings

Amendment: SEC Form 25-NSE/A filed by Merus N.V.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $MRUS

Amendment: SEC Form 25-NSE/A filed by Merus N.V.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $MRUS

$MRUS Analyst Ratings

Barclays initiated coverage on Merus with a new price target

Alliance Global Partners initiated coverage on Merus with a new price target

Piper Sandler initiated coverage on Merus with a new price target

$MRUS Insider Trading

Large owner Genmab A/S bought $79,098,068 worth of shares (815,444 units at $97.00) (SEC Form 4)

Large owner Genmab A/S bought $27,008,777 worth of shares (278,441 units at $97.00) (SEC Form 4)

Large owner Genmab A/S bought $26,340,059 worth of shares (271,547 units at $97.00) (SEC Form 4)

$MRUS FDA approvals

FDA Approval for BIZENGRI issued to MERUS N.V.

FDA Approval for BIZENGRI issued to MERUS N.V.

December 6, 2024 - FDA Roundup: December 6, 2024

$MRUS Press Releases

LeonaBio Reports First Quarter 2026 Financial Results and Provides Business Update

LeonaBio Enhances Board of Directors with Appointments of Fred Callori, J.D., Natalie Holles and Peter B. Silverman, J.D.

EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight

$MRUS Insider Purchases

Large owner Genmab A/S bought $79,098,068 worth of shares (815,444 units at $97.00) (SEC Form 4)

Large owner Genmab A/S bought $27,008,777 worth of shares (278,441 units at $97.00) (SEC Form 4)

Large owner Genmab A/S bought $26,340,059 worth of shares (271,547 units at $97.00) (SEC Form 4)

$MRUS SEC Filings

SEC Form 15-12G filed by Merus N.V.

Amendment: SEC Form SCHEDULE 13D/A filed by Merus N.V.